Etodolac: the chemistry, pharmacology, metabolic disposition, and clinical profile of a novel anti-inflammatory pyranocarboxylic acid.
L G Humber
Medicinal research reviews, 7(1), 1-28 (1987-01-01)
D R Brocks et al.
Clinical pharmacokinetics, 26(4), 259-274 (1994-04-01)
Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. Currently, the drug is available in several countries for the treatment of arthritis and the alleviation of pain. Etodolac possesses several unique disposition features mainly due...
Tetsuji Takayama et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 17(11), 3803-3811 (2011-03-10)
On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention...
Soad S Abd el-Hay et al.
Journal of fluorescence, 22(1), 247-252 (2011-08-20)
A simple, selective and sensitive luminescence method has been developed for the assay of etodolac (I), moxepril HCl (II) and fexofenadine HCl (III) in bulk drug and pharmaceutical formulations. The method is based on the luminescence sensitization of europium (Eu(3+))...
Yael Goldfarb et al.
Annals of surgery, 253(4), 798-810 (2011-04-09)
Surgical procedures, including primary tumor resection, have been suggested to suppress immune competence and to promote postoperative infections and cancer metastasis. Catecholamines and prostaglandins were recently implicated in these processes, and in directly promoting tumor angiogenesis and invasion. To examine...